Document is current
Any future updates will be listed below
-
Authors
Mattioli, Pietro https://orcid.org/0000-0003-2563-5830
Pardini, Matteo
Famà, Francesco
Girtler, Nicola
Brugnolo, Andrea
Orso, Beatrice
Meli, Riccardo
Filippi, Laura
Grisanti, Stefano
Massa, Federico
Bauckneht, Matteo
Miceli, Alberto
Terzaghi, Michele
Morbelli, Silvia
Nobili, Flavio
Arnaldi, Dario
- License Information
-
More Information
Article History
Received: 22 October 2020
Accepted: 17 January 2021
First Online: 28 January 2021
Compliance with ethical standards
:
: Matteo Pardini receives research support from Novartis and Nutricia, received fees from Novartis, Merck, and Biogen. Silvia Morbelli received speaking honoraria from G.E. healthcare. Flavio Nobili received fees from BIAL for consultation, from G.E. healthcare for teaching talks, and from Roche for board participation. Dario Arnaldi received fees from Fidia for lectures and board participation. All other authors declare no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by local ethics committee of the Istituto Nazionale per la Ricerca sul Cancro-IST, IRCCS San Martino polyclinic Hospital on May 31, 2013, (no. 703).
: Informed consent was obtained from all individual participants included in the study. The results of all the performed exams have been provided to the patients. Patients have been informed of the risk of phenoconversion, according to the “full disclosure” approach [] and information regarding the strategies to minimize the neurodegeneration risk were provided [].
